AMD: Hard Not To Be Bullish At This Valuation
Advanced Micro Devices' chiplet architecture in CPUs and GPUs positions it to outperform Nvidia in the inference market. See ...
AMD: The Strategy Beyond 'Disappointing' Quarter
AMD faces challenges from ARM's rise & NVIDIA's AI dominance. AI success is critical for growth as it lags with just 11% ...
New Buy Rating for Advanced Micro Devices (AMD), the Technology Giant
Benchmark Co. analyst Cody Acree reiterated a Buy rating on Advanced Micro Devices (AMD – Research Report) today and set a price target of ...
Prediction: Nvidia Stock Will Underwhelm After Feb. 26 for 3 Very Specific Reasons
After an extensive wait, artificial intelligence (AI) appears to have answered the call. Software and systems are being ...
1 US artificial intelligence (AI) chip stock to buy on the dip right now (Hint: It's not Nvidia)
Not all chip stocks have been soaring lately. The post 1 US artificial intelligence (AI) chip stock to buy on the dip right ...
AMD: Playing Second Fiddle To Nvidia Is No Fun (Downgrade)
AMD's cautious outlook and Nvidia's strong position in the AI market as the tech giants focus on AI CapEx investments in 2025 ...
Hosted on MSN1d
The Top-Performing Stocks of the Last Decade — And Their Returns
Every beginner investor secretly hopes they'll be the one to break the code and find that obscure startup just before it ...
Zacks.com on MSN1d
Investors Heavily Search Advanced Micro Devices, Inc. (AMD): Here is What You Need to Know
Advanced Micro Devices (AMD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...
Clearside reports progress in wet AMD treatment trials
ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...